Faculty

Connie Celum

Adjunct Professor, Epidemiology
Professor, Global Health
Professor, Medicine - Allergy and Infectious Dis.


Education

MD Medicine, University of California (San Francisco), 1984
MPH Epidemiology, University of Washington, 1989

Contact


Box 359927
University of Washington
Seattle, WA
University of Washington
Box 359927
Allergy and Infectious Diseases
Seattle, WA 98195

Research Interests

Dr. Celum's research currently focuses on HIV prevention and vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission. She utilizes epidemiologic data on behavioral and biologic risk factors for HIV acquisition and transmission to identify potential intervention strategies and then to conduct randomized clinical trials to determine safety and efficacy of these interventions with biologic outcome measurements. Her current effort is focused on sexually transmitted diseases (STDs), particularly genital herpes, as co-factors for HIV acquisition and transmission and clinical trials of candidate HIV vaccines. First, she is investigating HSV-2 as a co-factor for HIV acquisition and transmission, through a large randomized trial of daily antivirals for HSV-2 suppression to determine whether HIV acquisition can be reduced by 50% among HIV-negative, HSV-2 seropositive women in two African sites, and among MSM in Peru and two US sites. Second, to determine the effect of genital herpes on HIV infectiousness, she is conducting a large multi-center trial of HSV-2 suppression among HIV-discordant couples in Africa and India. Third, she is studying the effect of HSV-2 on mucosal HIV shedding with a double-blind cross-over study of valacyclovir among HIV/HSV-2 co-infected men and women in Peru. Fourth, she is studying the prevalence, incidence and risk factors for HSV-1 and HSV-2 acquisition among high-risk men who have sex with men in a multi-center trial of a behavioral intervention (Project Explore). Fifth, as part of her interest in the evaluation of HIV vaccine trials, she is developing approaches to assess the effect of partially-effective HIV vaccines on viral set-point and disease progression, including a standardized approach to provision of antiretroviral therapy for breakthrough infections in phase III trials.

Dr. Celum has developed research clinical units in Seattle and Lima, Peru, to conduct epidemiologic studies and clinical trials of HIV prevention interventions and vaccines. In addition, she serves as the PI on two multi-center international clinical trials of HSV-2 suppression and HIV transmission with sites in Africa, India, and Latin America, which provide opportunities for graduate students interested in studying the epidemiology of STD and HIV infection

HIV prevention; microbicide; vaccine trials with the objective to find effective strategies to reduce HIV acquisition and transmission.

Recent Publications (PubMed)

Undisclosed Antiretroviral Therapy Use at Primary Health Care Clinics in Rural KwaZulu Natal South Africa: A DO-ART Trial Sub-study.
(2021 Jun 7)
AIDS Behav
Sithole N, Gunda R, Koole O, Krows M, Schaafsma T, Moshabela M, Siedner MJ, Celum C, Barnabas RV

Laboratory Reflex and Clinic-based Point-of-care Cryptococcal Antigen Screening for Preventing Meningitis and Mortality among People Living with HIV.
(2021 May 10)
J Acquir Immune Defic Syndr
Drain PK, Galagan SR, Govere S, Krows M, Thulare H, Wallis CL, Gosnell BI, Moosa MY, Celum C, Bassett IV

A pilot evaluation of expedited partner treatment and partner HIV self-testing among adolescent girls and young women diagnosed with Chlamydia trachomatis and Neisseria gonorrhoeae in Kisumu, Kenya.
(2021 Apr 13)
Sex Transm Dis
Omollo V, Bukusi EA, Kidoguchi L, Mogaka F, Odoyo JB, Celum C, Morton J, Johnson R, Baeten JM

Cost of pre-exposure prophylaxis delivery in family planning clinics to prevent HIV acquisition among adolescent girls and young women in Kisumu, Kenya.
(2021)
PLoS One 16(4): e0249625
Wanga V, Peebles K, Obiero A, Mogaka F, Omollo V, Odoyo JB, Morton JF, Bukusi EA, Celum C, Baeten JM, Barnabas RV

Kidney injury biomarkers during exposure to tenofovir-based preexposure prophylaxis.
(2021 Jun 1)
AIDS 35(7): 1147-1149
Nickolas TL, Barasch J, Mugwanya KK, Branch AD, Heffron R, Wanga V, Mugo NR, Ronald A, Celum C, Donnell D, Baeten JM, Wyatt CM, Partners PrEP Study Team.

Show complete publication list